MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ejhf/xuag110

Медицинская библиотека · European journal of heart failure · 2026

Event rates of patients with stable heart failure with reduced ejection fraction and newly diagnosed obstructive or central sleep apnoea.

Horvath Christian M, Floras John S, Yatsu Shoichiro, Ishiwata Sayaki, Logan Alexander G, Tomlinson George, Bradley T Douglas, ADVENT-HF Investigators

СтатьяПеревод в очереди

Аннотация

AIMS: In patients with heart failure with reduced ejection fraction (HFrEF) and sleep-related breathing disorders, the predominant apnoea type may influence prognosis. The ADVENT-HF trial, which enrolled stable HFrEF patients with newly diagnosed obstructive (OSA) or central (CSA) sleep apnoea, provides a unique opportunity to perform a post-hoc analysis to test this hypothesis. We aimed to compare event rates between those with OSA and those with CSA following randomisation over the course of the trial.

METHODS

Cox-proportional hazard ratios (HR) were compared for: the primary composite endpoint (PE); all-cause; and cardiovascular mortality. Proportional-hazards assumption was assessed by Schoenfeld residuals' method.

RESULTS

Relative to OSA (n = 533), in unadjusted analyses, over the trial duration, the PE rate was greater in those with CSA (n = 198) (HR 1.38, 95%CI 1.10-1.73; P = .01), as were rates of all-cause (HR 1.72, 95%CI 1.26-2.36; P < .001) and cardiovascular mortality (HR 2.00, 95%CI 1.40-2.85; P < .001). These HRs were not statistically significant after adjustment for clinical characteristics associated with worse prognosis. Importantly, HRs varied over time, with an inflection point at one year. Adjusted HRs before and after 1 year were respectively 1.41 (95%CI 1.00-2.01, P = .051) and .91 (95%CI .65-1.26, P = .562) for the PE, 3.44 (95%CI 1.61-7.36, P = .001) and .89 (95%CI .58-1.37, P = .603) for all-cause mortality and 3.58 (95%CI 1.58-8.12, P = .002) and .92 (95%CI 0.56-1.51, P = 0.741) for cardiovascular mortality.

CONCLUSION

Detection of CSA in patients with stable HFrEF identifies a population at increased 1-year risk of adverse events who may benefit from earlier evaluation for advanced therapies or transplantation.

Для цитирования: Horvath Christian M, Floras John S, Yatsu Shoichiro, Ishiwata Sayaki, Logan Alexander G, Tomlinson George, Bradley T Douglas, ADVENT-HF Investigators. Event rates of patients with stable heart failure with reduced ejection fraction and newly diagnosed obstructive or central sleep apnoea.. European journal of heart failure. 2026. DOI: 10.1093/ejhf/xuag110.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.